دورية أكاديمية
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
| العنوان: | Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice |
|---|---|
| المؤلفون: | Dalvie, Neil C., Rodriguez-Aponte, Sergio A., Hartwell, Brittany L., Tostanoski, Lisa H., Biedermann, Andrew M., Crowell, Laura E, Kaur, Kawaljit, Kumru, Ozan S., Carter, Lauren, Yu, Jingyou, Chang, Aiquan, McMahan, Katherine, Courant, Thomas, Lebas, Celia, Lemnios, Ashley A., Rodrigues, Kristen A., Silva, Murillo, Johnston, Ryan S., Naranjo, Christopher, Tracey, Mary Kate, Brady, Joseph R., Whittaker, Charles A., Yun, Dongsoo, Brunette, Natalie, Wang, Jing Yang, Walkey, Carl, Fiala, Brooke, Kar, Swagata, Porto, Maciel, Lok, Megan, Andersen, Hanne, Lewis, Mark G., Love, Kerry R., Camp, Danielle L., Silverman, Judith Maxwell, Kleanthous, Harry, Joshi, Sangeeta B., Volkin, David B., Dubois, Patrice M., Collin, Nicolas, King, Neil P., Barouch, Dan H., Irvine, Darrell J, Love, Christopher J. |
| المساهمون: | Massachusetts Institute of Technology. Department of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology. Department of Biological Engineering, Harvard University--MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology. Institute for Medical Engineering & Science |
| المصدر: | PNAS |
| بيانات النشر: | National Academy of Sciences |
| سنة النشر: | 2021 |
| المجموعة: | DSpace@MIT (Massachusetts Institute of Technology) |
| الوصف: | Global containment of COVID-19 still requires accessible and affordable vaccines for low- and middle-income countries (LMICs). Recently approved vaccines provide needed interventions, albeit at prices that may limit their global access. Subunit vaccines based on recombinant proteins are suited for large-volume microbial manufacturing to yield billions of doses annually, minimizing their manufacturing cost. These types of vaccines are well-established, proven interventions with multiple safe and efficacious commercial examples. Many vaccine candidates of this type for SARS-CoV-2 rely on sequences containing the receptor-binding domain (RBD), which mediates viral entry to cells via ACE2. Here we report an engineered sequence variant of RBD that exhibits high-yield manufacturability, high-affinity binding to ACE2, and enhanced immunogenicity after a single dose in mice compared to the Wuhan-Hu-1 variant used in current vaccines. Antibodies raised against the engineered protein exhibited heterotypic binding to the RBD from two recently reported SARS-CoV-2 variants of concern (501Y.V1/V2). Presentation of the engineered RBD on a designed virus-like particle (VLP) also reduced weight loss in hamsters upon viral challenge. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0027-8424 1091-6490 |
| العلاقة: | http://dx.doi.org/10.1073/pnas.2106845118Test; Proceedings of the National Academy of Sciences; https://hdl.handle.net/1721.1/132697Test; Dalvie, Neil C. et al. "Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice." Proceedings of the National Academy of Sciences 118, 38 (September 2021): e2106845118. |
| الإتاحة: | https://doi.org/10.1073/pnas.2106845118Test https://hdl.handle.net/1721.1/132697Test |
| حقوق: | Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. |
| رقم الانضمام: | edsbas.D4687D8C |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 00278424 10916490 |
|---|